ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia
Marijn C. Meuwese(Amsterdam UMC Location University of Amsterdam), for the RED-CABG Steering Committee and Investigators(Northwestern Memorial Hospital), Dick C.G. Basart(Amsterdam UMC Location University of Amsterdam), Mieke D. Trip(Amsterdam UMC Location University of Amsterdam), Evan A. Stein(Oncotherapeutics (United States)), Aeilko H. Zwinderman(Amsterdam Neuroscience), Lee Schwocho(Amsterdam UMC Location University of Amsterdam), Leiv Ose(Oslo University Hospital), John J.P. Kastelein(QRx Pharma (United States)), Michael H. Davidson(Kiadis Pharma (Netherlands)), Frans Maritz(Amsterdam UMC Location University of Amsterdam), Eric de Groot(Amsterdam UMC Location University of Amsterdam), Raphaël Duivenvoorden(Radboud University Nijmegen), Rafik Habib(Amsterdam UMC Location University of Amsterdam)
Cited by 145
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k